Hans van der Saag
Chief Executive Officer @ BioActor
Maastricht, The Netherlands
Hans van der Saag is a Series A investor at BioActor in Maastricht focused on Health Care and Biotechnology. Hans van der Saag - Chief Executive Officer @ BioActor
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Hans van der Saag invests in
Stages Hans van der Saag invests in
Countries Hans van der Saag invests in
Investment Focus
Industry
- Health Care 1 (100%)
- Biotechnology 1 (100%)
- Dietary Supplements 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
BioActor
|
BioActor develops proprietary health ingredients for use in functional foods, medical nutrition and dietary supplements. All these ingredients address chronic health concerns, such as diabetes,osteoporosis, cardiovascular disease, that would benefit from preventative measures through the diet. BioActor's product development strategy relies onthree simple tenets: a new health ingredient must be based on a patentable scientific discovery; it must be food grade from a natural and renewable source; and its health effect must be clinically proven. BioActor's first product, BONOLIVE, a first in class bone health ingredient that is clinically proven to stimulate bone producing cells, is a great example of this strategy and will be launched in the USA this year. BioActor successfully implemented its product development strategy by establishing alliances with top nutrition research institutes (e.g. INRA, CSIC, Maastricht University, UCL, Ghent University) and by establishing production partnerships with industrial players to shorten the path to market. | $2.2M / Series A / Jul 26, 2011 |
Co-Investors
About BioActor
BioActor develops proprietary health ingredients for use in functional foods, medical nutrition and dietary supplements. All these ingredients address chronic health concerns, such as diabetes,osteoporosis, cardiovascular disease, that would benefit from preventative measures through the diet. BioActor's product development strategy relies onthree simple tenets: a new health ingredient must be based on a patentable scientific discovery; it must be food grade from a natural and renewable source; and its health effect must be clinically proven. BioActor's first product, BONOLIVE, a first in class bone health ingredient that is clinically proven to stimulate bone producing cells, is a great example of this strategy and will be launched in the USA this year. BioActor successfully implemented its product development strategy by establishing alliances with top nutrition research institutes (e.g. INRA, CSIC, Maastricht University, UCL, Ghent University) and by establishing production partnerships with industrial players to shorten the path to market.
BioActor Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Hans van der Saag
Chief Executive Officer
|
|||
|
Ariel Changyun Zhang
Business Development Manager for Asia Region
|
|||
Kevin Wilson
Commercial Manager of Health and Nutrition for Europe, Middle East, and Asia and North America
|
|||
Yala Stevens
Head of Clinical Research
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Hans van der Saag invest in?
Hans van der Saag invests primarily in Health Care, Biotechnology and Dietary Supplements startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Hans van der Saag last invest?
The most recent investment recorded for Hans van der Saag closed in Jul 2011. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
